Search

Sarepta Therapeutics Inc

Закрыт

СекторЗдравоохранение

19.97 -3.39

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

19.59

Макс.

20.11

Ключевые показатели

By Trading Economics

Доход

-4.9M

326M

Продажи

-330M

401M

P/E

Средняя по отрасли

42.919

56.432

Прибыль на акцию

0.42

Рентабельность продаж

81.263

Сотрудники

835

EBITDA

-345M

30M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+10.82% upside

Дивиденды

By Acuity

Следующий отчет о доходах

2 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

533M

2.2B

Предыдущая цена открытия

23.36

Предыдущая цена закрытия

19.97

Новостные настроения

By Acuity

40%

60%

70 / 339 Рейтинг в Healthcare

Sarepta Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

18 сент. 2026 г., 19:51 UTC

Sarepta Therapeutics Inc shares fell sharply, continuing a significant decline since Thursday and trading well below its 20-day moving average.

17 сент. 2026 г., 20:02 UTC

Sarepta Therapeutics Inc shares are sharply higher, showing notable volatility and remaining well above the 20-day moving average since Wednesday's close.

16 сент. 2026 г., 23:06 UTC

Sarepta Therapeutics Inc. is trading modestly higher in after-market hours following a notable early spike, despite closing lower in three consecutive sessions.

14 сент. 2026 г., 20:07 UTC

Sarepta Therapeutics shares are higher, reflecting broader market strength despite pulling back from an earlier session peak. No specific news was identified for the movement.

12 сент. 2026 г., 00:01 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading, following a decline earlier in the session amid broader inflation concerns ahead of a Federal Reserve meeting.

11 сент. 2026 г., 23:31 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours with no specific news to explain the decline amid broader market speculation on Federal Reserve rate hikes.

10 сент. 2026 г., 20:03 UTC

Sarepta Therapeutics Inc shares are lower today, continuing a decline since Wednesday. No specific news was identified to explain the drop.

9 сент. 2026 г., 23:21 UTC

Sarepta Therapeutics shares are lower in after-market hours, following a broader market trend amid rising U.S. Treasury yields impacting borrowing costs.

8 сент. 2026 г., 23:21 UTC

Social Media

Sarepta Therapeutics is higher in after-market trading amid social media interest in its $2.1 billion market cap and revenue projections for fiscal year 2026.

4 сент. 2026 г., 23:25 UTC

Sarepta Therapeutics Inc. shares declined after-market, reflecting unusual weakness since Friday's close, despite remaining above the 20-day moving average.

3 сент. 2026 г., 23:36 UTC

Sarepta Therapeutics Inc. shares traded roughly flat after market hours, while major indices gained amid easing interest rate concerns.

2 сент. 2026 г., 20:02 UTC

Social Media

Sarepta Therapeutics shares are higher as investor interest grows ahead of clinical data for treatments targeting muscular dystrophy, despite a pullback from session highs.

1 сент. 2026 г., 20:09 UTC

Sarepta Therapeutics Inc shares are higher today, supported by gains in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

31 авг. 2026 г., 20:07 UTC

Sarepta Therapeutics shares are higher amid broader market concerns over inflation, with no specific company news identified to explain the movement.

28 авг. 2026 г., 19:51 UTC

News

Sarepta Therapeutics reported a 34% revenue decline to $401.3 million for Q2 2026, as execution risks weigh on shares during the current session.

27 авг. 2026 г., 23:02 UTC

Sarepta Therapeutics shares declined in after-market trading amid a broader market pullback, despite earlier gains during the session. No specific news was identified.

26 авг. 2026 г., 20:08 UTC

Sarepta Therapeutics Inc shares are higher today amid broader market gains, despite no specific company news identified. Recent inflation data may be influencing market trends.

25 авг. 2026 г., 19:26 UTC

Sarepta Therapeutics Inc. shares are higher today amid notable volatility, despite no specific news to explain the movement. Broader market conditions support higher valuations.

24 авг. 2026 г., 20:06 UTC

News

Sarepta Therapeutics shares decline amid investigation into potential fiduciary breaches and safety concerns regarding its gene therapy, Elevidys.

21 авг. 2026 г., 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

20 авг. 2026 г., 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

19 авг. 2026 г., 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

18 авг. 2026 г., 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

17 авг. 2026 г., 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

14 авг. 2026 г., 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

13 авг. 2026 г., 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

12 авг. 2026 г., 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

11 авг. 2026 г., 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

10 авг. 2026 г., 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

7 авг. 2026 г., 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

Сравнение c конкурентами

Изменение цены

Sarepta Therapeutics Inc Прогноз

Целевая цена

By TipRanks

10.82% рост

Прогноз на 12 месяцев

Средняя 22.286 USD  10.82%

Максимум 38 USD

Минимум 5 USD

Основано на мнении 16 аналитиков Wall Street, спрогнозировавших целевые цены для Sarepta Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

16 ratings

4

Покупка

8

Удержание

4

Продажа

Настроения

By Acuity

70 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.